A doxorubicin–platinum conjugate system: impacts on PI3K/AKT actuation and apoptosis in breast cancer cells

• DOI: 10.1039/d0ra06708c
• Publication Date: 2021-01-25T15:58:48Z
• Authors: Puja Patel; Devan Umapathy; Selvambigai Maniv...; Vinita Manimaran ...; Rajiu Venkatesan; Velanganni Antony...; Srinivasan Pappu; Kumar Ponnuchamy
• Keywords: Conjugate

In recent years, the development of a nano-conjugate system for drug delivery applications has gained attention among researchers. Keeping this in mind, study, we developed doxorubicin-platinum conjugate that targeted breast cancer cell lines. To achieve this, platinum nanoparticles using polyvinylpyrrolidone (PVP). High resolution-transmission electron microscopy (HR-TEM) revealed occurrence octopod-shaped nanoparticles. Subsequently, doxorubicin (DOX) was conjugated on surface as-prepared octopods via an situ stirring method. The physicochemical characterization PVP PtNPs interacts with NH2 group electrostatic interaction/hydrogen bonding. Besides, exhibited sustained release profile within cells. Furthermore, evaluation vitro anticancer efficacy cells (MCF-7 and MDA-MB-231) unveiled induction apoptosis intracellular ROS DNA damage, rather than free DOX PtNPs. Remarkably, also perceived strong enough to down-regulate PI3K/AKT signalling pathway. As result, tumour suppressor gene PTEN activated, which led stimulation mitochondrion-based intrinsic apoptotic pathway its downstream caspases, triggering death. Hence, our findings suggested biologically stable could be imperative therapeutic agent therapy near future.